How Factor V Leiden Affects Pregnancy and Blood Clot Risk

Factor V Leiden is the most common inherited blood-clotting disorder, and pregnancy is one of the situations where it matters most. The mutation makes your blood more prone to forming clots, and pregnancy independently pushes your clotting system in the same direction, so the two together raise the risk of venous thromboembolism and, to a lesser extent, certain pregnancy complications. For most carriers, though, the absolute risk remains low enough that a well-managed pregnancy is the expected outcome, not the exception.

Why Pregnancy Makes Factor V Leiden Riskier

Your body ramps up its clotting capacity during pregnancy as a protective measure against hemorrhage at delivery. Levels of several clotting factors rise, natural anticoagulant activity drops, and blood flow in the legs slows as the uterus grows. This shift toward easier clotting is normal and, in evolutionary terms, beneficial. But it also means that anyone who already clots more readily than average starts pregnancy at a disadvantage.

Factor V Leiden works by making one specific clotting protein resistant to the molecule that normally shuts it off. When pregnancy layers its own pro-clotting changes on top of that resistance, the combined effect is greater than either alone.¹ The interaction between the inherited mutation and the acquired state of pregnancy is what makes this a genuinely different clinical picture from carrying the mutation outside of pregnancy.²

How Much the Blood Clot Risk Actually Rises

The numbers depend heavily on whether you carry one copy of the mutation (heterozygous) or two (homozygous), and on whether you have a personal or family history of clots. Most carriers are heterozygous, and for them the picture is reassuring in absolute terms even though the relative risk sounds alarming.

A large Bayesian meta-analysis estimated the absolute risk of pregnancy-associated venous thromboembolism in heterozygous carriers at roughly 1 in 100 overall, with the risk split unevenly between pregnancy (about 0.4%) and the postpartum period (about 2%).³ Women identified through family studies, meaning a relative had already had a clot, faced a higher absolute risk of about 2.4%, compared with roughly 0.4% in population-based studies where carriers were found through routine screening.⁴ That distinction matters: it means your personal history and family history change the numbers more than the mutation alone.

A separate meta-analysis found the odds of a first pregnancy-related blood clot were roughly four to five times higher in heterozygous carriers than in non-carriers, with case-control studies suggesting an even larger gap.⁵ Another study estimated the rate at about 5 per 1,000 heterozygous pregnancies, compared with about 1 per 1,000 in non-carriers.⁶

Homozygous carriers face a substantially steeper risk. The Bayesian meta-analysis placed their absolute risk at roughly 6%, though with very wide uncertainty, and one study found that every homozygous carrier in the cohort developed a clot during pregnancy or the puerperium.⁷ ⁸ Women who carry Factor V Leiden alongside a second clotting mutation, such as the prothrombin gene variant, also face dramatically higher risk, with one study reporting venous thromboembolism in 20% of double heterozygous carriers.⁹

Does Factor V Leiden Cause Miscarriage?

This is one of the questions that generates the most anxiety, and the evidence is surprisingly mixed. A meta-analysis of studies on early recurrent pregnancy loss found that carriers of Factor V Leiden did have a modestly higher rate of recurrent miscarriage, with odds about 1.7 times those of non-carriers.¹⁰ That sounds meaningful, but individual studies within that body of research often found no significant link at all.¹¹ ¹²

The picture that emerges is that the mutation may contribute a small amount of additional risk for recurrent miscarriage, but it is far from a reliable predictor. Population differences, study quality, and how miscarriage is defined all muddy the water. Researchers studying Indian populations, for instance, have concluded that routine testing for Factor V Leiden in women with recurrent loss is not justified in that context because the association simply does not hold up.¹³ So if you carry the mutation and have experienced miscarriage, the mutation might be part of the picture, but it is unlikely to be the whole explanation.

Preeclampsia, Growth Restriction, and Other Placental Complications

There has been a long-standing hypothesis that because Factor V Leiden promotes micro-clotting, it could impair blood flow through the placenta and lead to preeclampsia, intrauterine growth restriction, or stillbirth. The evidence for this has weakened substantially over the last two decades.

A systematic review and meta-analysis of prospective studies found that Factor V Leiden did not significantly increase the risk of preeclampsia: the absolute rate was 3.8% in carriers versus 3.2% in non-carriers, a gap that was not statistically meaningful.¹⁴ The same meta-analysis found no increased risk of small-for-gestational-age babies among carriers.¹⁵ An earlier meta-analysis of case-control studies had suggested a nearly three-fold increase in intrauterine growth restriction, but the authors themselves cautioned that the finding may have been driven by small, low-quality studies with extreme results.¹⁶

Pathology studies have found that placentas from Factor V Leiden pregnancies do sometimes show signs of reduced blood flow, including areas of tissue receiving less oxygen.¹⁷ But visible changes under a microscope and clinically meaningful complications are two different things. The current weight of evidence, especially from prospective studies that follow women forward rather than looking backward from a complication, suggests the mutation is not a strong independent risk factor for preeclampsia or growth restriction.

Preventing Blood Clots During Pregnancy

The main tool for reducing clot risk in pregnant women with Factor V Leiden is low-molecular-weight heparin, an injectable blood thinner that does not cross the placenta and has a well-established safety record in pregnancy.¹⁸ Not every carrier needs it, though. The decision hinges on whether you are heterozygous or homozygous, whether you have had a previous clot, and whether you have additional risk factors like obesity, immobility, or a second inherited clotting mutation.

In general, heterozygous carriers with no personal or strong family history of clots are often monitored closely without prophylactic anticoagulation during pregnancy, though postpartum prophylaxis may still be recommended because the weeks after delivery carry the highest risk. Homozygous carriers and those with a prior clot almost always receive heparin throughout pregnancy and for several weeks postpartum.

One study of carriers of Factor V Leiden or the prothrombin mutation found that low-molecular-weight heparin roughly halved the odds of miscarriage and dramatically reduced the odds of blood clots during pregnancy.¹⁹ The benefit was strongest in women who already had a history of obstetric complications. A trial comparing aspirin alone, heparin alone, and the combination in women with recurrent pregnancy loss and the mutation found that all three approaches produced similar live-birth rates, though the heparin-containing regimens were associated with lower rates of preeclampsia and preterm birth.²⁰

The Postpartum Period Is the Highest-Risk Window

If there is one thing carriers should understand clearly, it is that the weeks immediately after delivery carry more risk than pregnancy itself. The clotting system remains in overdrive for about six to eight weeks postpartum, and the physical recovery from delivery adds additional risk factors like reduced mobility and tissue injury. In the Bayesian meta-analysis mentioned earlier, the postpartum absolute risk for heterozygous carriers was roughly 2%, compared with about 0.4% during the pregnancy itself.²¹ A study focused specifically on pregnancy-related clot events found that the majority occurred postpartum rather than during pregnancy.²²

This is why some clinical guidelines recommend anticoagulant prophylaxis for six weeks after delivery even for heterozygous carriers who did not receive it during pregnancy. Staying mobile, wearing compression stockings, staying hydrated, and knowing the symptoms of deep vein thrombosis and pulmonary embolism are all part of postpartum care for carriers.

Anesthesia and Delivery Planning

If you are receiving heparin injections, the timing of your last dose matters for labor and delivery, particularly if you want an epidural or spinal anesthesia. Inserting a needle near the spinal cord in a patient whose blood is thinned carries a small risk of a spinal hematoma, which is a serious complication. For this reason, anesthesiologists recommend that carriers on low-molecular-weight heparin switch to unfractionated heparin before the 38th week of pregnancy, because unfractionated heparin clears the body faster, making it easier to time a safe window for neuraxial anesthesia.²³

The practical takeaway is that your anesthesiologist should know about your mutation and your anticoagulation plan well before your due date, not when you arrive in labor. A conversation during the third trimester gives the care team time to coordinate the switch and plan around it.

Should You Be Tested?

Universal screening of all pregnant women for Factor V Leiden is not recommended. The absolute risk of complications in carriers is low enough that blanket testing would lead to widespread overtreatment, anxiety, and costs that are not offset by the number of events prevented.²⁴ A cost-effectiveness analysis estimated that universal screening would prevent fewer than three vascular events at a management cost of nearly 40,000 pounds per screened cohort, while selective screening fared only slightly better.²⁵

Testing is generally considered appropriate in more targeted situations: if you have a personal history of blood clots, a strong family history of clots especially at a young age, a first-degree relative with a known clotting mutation, or a history of pregnancy complications that suggest placental blood flow problems. Even then, identifying the mutation does not automatically change management unless the clinical context supports starting anticoagulation.

Oral Contraceptives Before Pregnancy

A related concern comes up before pregnancy ever begins. Combined oral contraceptives themselves raise clot risk, and the combination of the pill and Factor V Leiden multiplies the odds substantially. One study found that carriers using oral contraceptives faced roughly ten times the odds of a blood clot compared with women who neither carried the mutation nor used the pill.²⁶ If you know you carry the mutation and are planning a pregnancy, this interaction is worth discussing with your provider when choosing contraception in the months or years beforehand. Progestin-only methods or non-hormonal options sidestep the added risk.

IVF and Factor V Leiden

Women undergoing in vitro fertilization sometimes worry that the mutation will reduce their chances of success or increase the risk of complications like ovarian hyperstimulation syndrome. A prospective cohort study following carriers through up to six IVF cycles found that the cumulative live-birth rate was similar in carriers and non-carriers, and there was no increased risk of hyperstimulation or thrombosis during treatment.²⁷ The authors concluded that screening for the mutation was not justified solely to predict IVF outcomes. A separate study did find a higher prevalence of Factor V Leiden among women with recurrent IVF failure, but this was a case-control comparison, a weaker design that cannot establish cause and effect.²⁸ At present, the mutation is not considered a reason to avoid or modify standard IVF protocols in otherwise low-risk women.

What About the Baby?

Factor V Leiden follows a straightforward inheritance pattern. If one parent carries one copy, each child has a 50% chance of inheriting it. If both parents carry a copy, there is a 25% chance the child will be homozygous. For the vast majority of babies who inherit the mutation, it will have no clinical consequence during infancy or childhood. The mutation is present in roughly 5% of people of European descent, and most live their entire lives without a clot.

In rare cases, however, the mutation has been linked to neonatal clotting events. Case reports have described neonatal stroke in a heterozygous infant and renal vein thrombosis in a newborn carrying both Factor V Leiden and the prothrombin mutation.²⁹ ³⁰ Early reports also identified the mutation in babies with placental blood vessel clots and cerebral palsy from in-utero stroke.³¹ These are extremely uncommon events, and the mutation is one possible contributor among many rather than a reliable cause. Routine testing of newborns for Factor V Leiden is not standard practice.

Why Such a Risky Mutation Is So Common

Something that puzzles a lot of people: if Factor V Leiden increases the risk of dangerous blood clots, why does it persist in such a large share of the population? Up to 15% of people in some European populations carry at least one copy, which is far too common to be explained by random chance alone.³²

The leading explanation is that the mutation provides survival advantages that historically outweighed its clotting risks. In women, enhanced clotting may have reduced the risk of fatal hemorrhage during childbirth, a major cause of death for most of human history. Carriers also appear to maintain higher hemoglobin levels, which could matter in environments with chronic blood loss from parasites or nutritional deficiency.³³ There is also evidence from both human sepsis trials and mouse studies that heterozygous carriers have a survival advantage during severe bloodstream infection, possibly because the slightly pro-clotting state helps contain bacteria.³⁴ Homozygous carriers did not show the same protection, which fits a pattern where one copy of the mutation is beneficial but two copies tip the balance toward harm. The modern downside of the mutation, blood clots during pregnancy, surgery, or air travel, may simply be the price of an adaptation that was overwhelmingly useful for most of evolutionary history.